Next-generation cancer diagnostics and therapy guidance of lung and breast cancer patients using mass spectrometry-based proteomics (Q84323)
Jump to navigation
Jump to search
Project Q84323 in Poland
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Next-generation cancer diagnostics and therapy guidance of lung and breast cancer patients using mass spectrometry-based proteomics |
Project Q84323 in Poland |
Statements
1,747,280.0 zloty
0 references
1,747,280.0 zloty
0 references
100.0 percent
0 references
1 September 2018
0 references
31 August 2021
0 references
INSTYTUT BIOCHEMII I BIOFIZYKI POLSKIEJ AKADEMII NAUK
0 references
The proposal will establish a team in the field of mass spectrometry (MS)-based clinical proteomics in cancer research which will develop technologies to advance pre-clinical research and create practical applications towards use in the clinical laboratory. The aims are the advancement of cancer research, and improvement of cancer diagnostics, prognosis and therapy monitoring. The applicant is an expert in the field, with knowledge gained at research units in Canada and Poland. He brings eight years of experience in a flourishing field of targeted proteomics, with knowledge in applying its technology to translational and medical research, with great future potential in clinical applicability. The know-how will be transferred to three students and combined with interdisciplinary collaborations with medical doctors in Canada and Poland creating a team which will advance the field so it can enter the clinical realm and create specific applications for breast and lung cancer diagnosis. (Polish)
0 references
The proposal will establish a team in the field of mass spectrometry (MS)-based clinical proteomics in cancer research which will develop technologies to advance pre-clinical research and create practical applications towards use in the clinical laboratory. The goals are the advancement of cancer research, and improvement of cancer diagnostics, prognosis and therapy monitoring. The applicant is an expert in the field, with knowledge gained at research units in Canada and Poland. He brings eight years of experience in a flourishing field of targeted proteomics, with knowledge in applying its technology to translational and medical research, with great future potential in clinical applicability. The know-how will be transferred to three students and combined with interdisciplinary collaborations with medical doctors in Canada and Poland creating a team which will advance the field so it can enter the clinical realm and create specific applications for breast and lung cancer diagnosis. (English)
14 October 2020
0 references
Identifiers
POIR.04.04.00-00-4647/17
0 references